Cost Analysis of Autologous Peripheral Stem Cell Transplantation Versus Autologous Bone Marrow Transplantation for Patients with Non Hodgkin's Lymphoma and Acute Lymphoblastic Leukaemia

References

• Wunder E. W., Henon P. R. Peripheral blood stem cell autograft. Springer-Verlag, Berlin Heidelberg 1993
   Google Scholar
• Fliedner T. M., Flad H. D., Bruch C., et al. Treatment of aplastic anemia by blood stem cell transfusion: a canine model. Haematologica. 1976; 61: 141–156
   PubMedGoogle Scholar
• Goldman J. M., Th'ng K. H., Park D. S., et al. Collection, cryopreservation and subsequent viability of hae-mopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation. Br J Haematol 1978; 40: 185–195
   PubMed Web of Science ®Google Scholar
• Korbling M., Burke P., Braine H., et al. Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 1981; 9: 684–690
   PubMed Web of Science ®Google Scholar
• Juttner C. A., To L. B., Haylock D. N., et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose mel-phalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61: 739–745
   PubMed Web of Science ®Google Scholar
• Micklem H. S., Anderson N., Ross E., et al. Limited potential of circulating haemopoietic stem cells. Nature 1975; 256: 4143
   Web of Science ®Google Scholar
• Hibbin J. A., Njoku S. O., Matutes E., et al. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol. 1984; 57: 495–503
   PubMed Web of Science ®Google Scholar
• Korbling M., Dorken B., Ho A. D., et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood. 1986; 67: 529–532
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Siena S., Bregni M., et al. Granulo-cyte-macrophage colony-stimulating factor to harvest circulating haernopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–585
   PubMed Web of Science ®Google Scholar
• Fukuda M., Kojima S., Matsumoto K., et al. Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma. Br J Haemnatol 1992; 80: 327–331
   PubMed Web of Science ®Google Scholar
• Mahendra P., Johnson D., Scott M. A., et al. Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients. Bone Marrow Transplant. 1996; 17: 503–507
   PubMed Web of Science ®Google Scholar
• Bender J. G., To L. B., Williams S., et al. Defining a therapeutic dose of peripheral blood stem cells. J Hem-rother 1992; 329–341
   Google Scholar
• Martino M., Morabito F., Messina G., et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haemnat logica. 1996; 81: 59–61
   PubMed Web of Science ®Google Scholar
• Gaspard M. H., Maraninchi D., Stoppa A. M., et al. Intensive chemotherapy with high doses of BCNU, etopo-side, cytosine arabinoside. and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22: 256–262
   PubMed Web of Science ®Google Scholar
• Mills W., Chopra R., McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patienh with relapsed or refractory non-Hodgkin's lymphoma. J CIin Oncol 1995; 13: 588–595
   PubMed Web of Science ®Google Scholar
• Rapoport A. P., Rowe J. M., Kouides P. A., et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J-Clin Oncol 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Raemaekers J., de Witte T., Schattenberg A., et al. Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthra-cyclines. Bone Marrow Transplant 1989; 4: 167–171
   PubMed Web of Science ®Google Scholar
• Stockerl G. K., Homing S. J., Negrin R. S., et al. Influence of preparatory regimen and source of hematopoie-tic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 7685
   Google Scholar
• Spitzer T. R., Cottler F., Torrisi J., et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989; 4: 559–565
   PubMed Web of Science ®Google Scholar
• Coulombel L., Kalousek D. K., Eaves C. J., et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic rnyelogenous leukemia. N EnglJMed 1983; 308: 1493–1498
   PubMed Web of Science ®Google Scholar
• Gilbert C. J. Peripheral blood progenitor cell transplantation for breast cancer: pharmacoeconomic considerations. Pharmacotherapv 1996; 16: 101s–108s
   PubMed Web of Science ®Google Scholar
• Inaba S., Ohno Y., Mizuno S., et al. [The progress of autologous peripheral blood stem cell transplantation]. Nippon Rinsho. 1995; 53: 779–789
   PubMedGoogle Scholar
• Takaue Y., Okamoto Y., Kawano Y., et al. Regeneration of immunity and varicella-zoster virus infection after high-dose chemotherapy and peripheral blood stem cell autografts in children. Bone Marrow Transplant 1994; 14: 219–223
   PubMed Web of Science ®Google Scholar
• Grenman S. E., Rantanen V. T., Salmi T. A., et al. High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer. Ann Med 1996; 28: 151–158
   PubMed Web of Science ®Google Scholar
• Fetscher S., Brugger W., Bertz H., et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for metastatic gastric leiomyosarcoma. Bone Marrow Transplant 1997; 20: 787–788
   PubMed Web of Science ®Google Scholar
• Fetscher S., Brugger W., Engelhardt R., et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Ann Oncol 1997; 8: 49–56
   PubMed Web of Science ®Google Scholar
• Fetscher S., Brugger W., Engelhardt R., et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-disease non-small-cell lung cancer. Ann Oncol 1997; 8: 57–64
   PubMed Web of Science ®Google Scholar
• Fetscher S., Kiani A., Kanz L., et al. Neo-adjuvant high-dose chemotherapy with autologous peripheral blood stem cell transplantation for inoperable relapse of nuchal liposarcoma resistant to standard-dose chemotherapy [letter]. Ann Oncol 1996; 7: 871
   PubMed Web of Science ®Google Scholar
• Smith T. J., Hillner B. E., Schmitz N., et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5–10
   PubMed Web of Science ®Google Scholar
• Hartmann O., le Corroller A. G., Blaise D., et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann lntrern Med 1997; 126: 600407
   Web of Science ®Google Scholar
• Henon P., Dondtini B., Eisenmann J. C., et al. Comparative survival. quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant 1995; 16: 19–25
   PubMed Web of Science ®Google Scholar
• Duncan N., Hewetson M., Powles R., et al. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1996; 18: 1175–1178
   PubMed Web of Science ®Google Scholar
• Faucher C., le Corroller A. G., Blaise D., et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994; 14: 895–901
   PubMed Web of Science ®Google Scholar
• Rio B., Majanovic Z., Belhocine R., et al. [Difference in costs of autologous transplantation of peripheral and bone marrow hematopoietic stem cells. A retrospective analysis over 1 year of transplantation in lymphoma, Hodgkin's disease and myeloma in a Center] Difference de cout des autogreffes de cellules-souches hematopoietiques circulantes et medullaires. Ann Med Interne Paris 1996; 147: 313–319
   PubMedGoogle Scholar
• Julia A., Bueno J., Gadea N., et al. [Economic study of the cost of peripheral blood hematopoietic precursor autotransplantation compared with bone marrow transplantation]. Med Clin Barc 1995; 105: 131–135
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Armitage J. L., Armitage G. O., et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995; 13: 969–973
   PubMed Web of Science ®Google Scholar
• Lawless G. D. Cost-effectiveness of autologous bone marrow transplantation. Am J Healrh Syst Pharm. 1995; 52: S11–S14
   PubMedGoogle Scholar
• Jones H. M., Jones S. A., Watts M. J., et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693–1702
   PubMed Web of Science ®Google Scholar
• Souetre E., Qing W., Penelaud P. F., et al. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur J-Cancer 1996; 32a: 1162–1165
   PubMed Web of Science ®Google Scholar
• Klumpp T. R., Mangan K. F., Goldberg S. L., et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J -Clin Oncol 1995; 13: 1323–1327
   PubMed Web of Science ®Google Scholar
• Gulati S., Bennett C., Toia M., et al. Role of granu-locyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease. Anticancer Drugs. 1993; 1: 13–16
   Web of Science ®Google Scholar
• Weaver A., Ryder D., Crowther D., et al. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996; 88: 3323–3328
   PubMed Web of Science ®Google Scholar
• Glaspy J. A., Shpall E. J., LeMaistre C. F., et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939–2951
   PubMed Web of Science ®Google Scholar
• Weaver C. H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969
   PubMed Web of Science ®Google Scholar
• Ketterer N., Salles G., Raba M., et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155
   PubMed Web of Science ®Google Scholar
• Gonzalez R., Madero L., Diaz M. A., et al. Progenitor cell subsets and engraftment lanetics in children undergoing autologous peripheral blood stem cell transplantation. Br J Haematol 1998; 101: 104–110
   PubMed Web of Science ®Google Scholar